Trail Antibody
| Code | Size | Price |
|---|
| PSI-1113-0.02mg | 0.02mg | £150.00 |
Quantity:
| PSI-1113-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Documents
Further Information
Additional Names:
Trail Antibody: TL2, APO2L, CD253, TRAIL, Apo-2L, Tumor necrosis factor ligand superfamily member 10, Apo-2 ligand
Application Note:
TRAIL antibody can be used for detection of TRAIL by Western blot at 1 - 5 μg/mL dilution. Antibody can also be used for immunohistochemistry starting at 20 μg/mL.
Antibody validated: Western Blot in human samples; Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Antibody validated: Western Blot in human samples; Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Background:
Trail Antibody: Apoptosis, or programmed cell death, occurs during normal cellular differentiation and development of multicellular organisms. Apoptosis is induced by certain cytokines including TNF and Fas ligand in the TNF family through their death domain containing receptors, TNFR1 and Fas. TRAIL (TNF-related apoptosis-inducing ligand) is a type II membrane protein and expressed in a variety of human tissues (1,2). The death domain containing receptors DR4 and DR5 have been identified as the receptor for TRAIL (3-6). Like TNF and Fas ligand, TRAIL induces apoptosis and NF-κB activation in many tissues and cells.
Background References:
- Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995; 3:673-82.
- Pitti RM, Marsters SA, Ruppert S, et al. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J. Biol. Chem. 1996; 271:12687-90.
- Pan G, O'Rourke K, Chinnaiyan AM, et al. The receptor for the cytotoxic ligand TRAIL. Science; 1997; 276:111-3.
- Schneider P, Thome M, Burns K, et al. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-κB. Immunity 1997; 7:831-6.
Buffer:
Trail Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/ml
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Homology:
Predicted species reactivity based on immunogen sequence: Mouse: (82%)
Immunogen:
TRAIL antibody was raised against a peptide corresponding to 17 amino acids near the carboxy terminus of human TRAIL.
The immunogen is located within the last 50 amino acids of Trail.
The immunogen is located within the last 50 amino acids of Trail.
NCBI Gene ID #:
8743
NCBI Official Name:
tumor necrosis factor (ligand) superfamily, member 10
NCBI Official Symbol:
TNFSF10
NCBI Organism:
Homo sapiens
Physical State:
Liquid
PREDICTED MOLECULAR WEIGHT:
Predicted: 32 kDa
Observed: 35 kDa
Observed: 35 kDa
Protein Accession #:
NP_003801
Protein GI Number:
4507593
Purification:
Trail Antibody is affinity chromatography purified via peptide column.
Research Area:
Apoptosis,Cancer
Swissprot #:
P50591
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
| Product Name | Product Code | Supplier | TRAIL Peptide | PSI-1113P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|